clinical trials & evidence

RGN-259, RegeneRx ophthalmology trials, wound healing studies, and the critical evidence gaps

Where's the Human Data?

the clinical development of thymosin beta-4 has been led primarily by RegeneRx Biopharmaceuticals, which developed RGN-259 -- a sterile ophthalmic solution of Tb4 -- for dry eye disease and neurotrophic keratopathy. these represent the furthest any Tb4 product has advanced in formal clinical trials. for injectable TB-500 as used in the biohacking community, there are no completed randomized controlled human trials. understanding this evidence gap is essential for evaluating any claims about TB-500.

Interactive Trial Pipeline

Explore the clinical trial timeline for thymosin beta-4 products.

clinical trial pipeline

Knowledge Check

Test what you've learned in this unit.

Practice Exercises

Reinforce your understanding.